title: Impact of statin therapy on plasma resistin and visfatin concentrations: A systematic review and meta-analysis of controlled clinical trials.
abstract: The beneficial effects of statin therapy in reducing cardiovascular morbidity and mortality is not merely explained by the lipid-modulating effects. Although adipokines levels have been associated with cardiometabolic disorders, a few studies have explored the effect of statin on resistin and visfatin. We aimed to evaluate the impact of statin therapy on levels of resistin and visfatin through a meta-analysis of published studies. A systematic literature search in Medline and SCOPUS databases was conducted up to January 2015 to identify controlled trials assessing changes in plasma concentrations of visfatin and resistin during treatment with statins. Quantitative data synthesis was performed using a random-effects model, with weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics. 12 eligible studies with 14 treatment arms were included. Overall, 844 participants were studied. No significant change in plasma resistin concentrations was observed following statin therapy (WMD: -0.11ng/mL, CI: -1.94,1.73, p=0.909). This effect was robust and not affected by statin type, treatment duration and LDL-cholesterol concentrations. With respect to visfatin concentrations, there was a marginally significant reduction following statin therapy (WMD: -2.40ng/mL, CI: -4.79,-0.002, p=0.050). However, this effect size was weak and sensitive to three of the trials included in the analysis. This meta-analysis did not suggest any effect of statin therapy on plasma resistin levels, while a slight reduction in visfatin levels was found. The effect of statins on visfatin levels may represent a novel pleiotropic characteristic of these drugs.
authors.affiliation: Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
authors.forename: Amirhossein
authors.initials: A
authors.lastname: Sahebkar
authors.affiliation: Department of Life, Health & Environmental Sciences, University of L⿿Aquila, Italy. Electronic address: pa.giorgini@gmail.com.
authors.forename: Paolo
authors.initials: P
authors.lastname: Giorgini
authors.affiliation: Department of Life, Health & Environmental Sciences, University of L⿿Aquila, Italy.
authors.forename: Valeria
authors.initials: V
authors.lastname: Ludovici
authors.affiliation: Area di Geriatria, Università Campus Biomedico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Pedone
authors.affiliation: Dipartimento di Scienze cliniche Specialistiche ed Odontostomatologiche (DISCO), Università Politecnica delle Marche, Italy.
authors.forename: Gianna
authors.initials: G
authors.lastname: Ferretti
authors.affiliation: Dipartimento di Scienze della Vita e dell⿿Ambiente (DISVA), Università Politecnica delle Marche, Italy.
authors.forename: Tiziana
authors.initials: T
authors.lastname: Bacchetti
authors.affiliation: Department of Life, Health & Environmental Sciences, University of L⿿Aquila, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Grassi
authors.affiliation: Department of Life, Health & Environmental Sciences, University of L⿿Aquila, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Di Giosia
authors.affiliation: Department of Life, Health & Environmental Sciences, University of L⿿Aquila, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Ferri
mesh_terms: D015415:Biomarkers / Q000097:blood; D018849:Controlled Clinical Trials as Topic; D016207:Cytokines / Q000097:blood*; D050171:Dyslipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D052243:Resistin / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; C499624:RETN protein, human; D052243:Resistin; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human
keywords: Adipokines; Pleiotropic effect; Resistin; Statin; Visfatin